Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player...

Area of Science:

• Immunology
• Oncology
• Cancer Immunotherapy

Background:

• Immune checkpoint pathways, such as PD-1/PD-L1 signaling, are crucial for immune regulation but can be exploited by cancer cells to evade immune surveillance.
• PD-1/PD-L1 targeted therapy has emerged as a significant advancement in cancer immunotherapy, demonstrating efficacy across various malignancies.

Purpose of the Study:

• To review the mechanistic aspects of the PD-1/PD-L1 signaling pathway.
• To explore the regulatory mechanisms governing this pathway.
• To assess PD-1/PD-L1 as a predictive and prognostic marker in diverse cancers and examine methods for measuring PD-L1 expression.

Main Methods:

• A comprehensive review of existing medical literature concerning PD-L1 expression in various cancers.
• Inclusion of preliminary findings from the Blue Proposal, which evaluated different immunohistochemical stains for PD-L1, presented at the 2016 AACR Annual Meeting.

Main Results:

• PD-1/PD-L1 targeted therapy, both as monotherapy and in combination regimens, offers therapeutic advantages for patients with advanced cancers.
• The complex interplay of cancer immunity currently limits the availability of a definitive biomarker for predicting response to PD-1/PD-L1 targeted therapies.

Conclusions:

• PD-1/PD-L1 targeted therapies represent a valuable treatment option for advanced cancers, either alone or in combination with other modalities.
• The development of reliable biomarkers is essential for optimizing patient selection for PD-1/PD-L1 targeted therapy, requiring further investigation beyond current immunohistochemical methods.